Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)
Lund, Sweden, 31 May 2018 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced an increase of the number of shares and votes in NeuroVive of 39,244,644 as a result of a preferential rights issue in NeuroVive Pharmaceutical AB, approved at the Extraordinary General Meeting on 22 March 2018.Today, the last trading day of the month, there are in total 91,570,841 shares and votes in NeuroVive Pharmaceutical AB. This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the